TABLE 3.

Susceptibility of the mutant replicon variants with and without the C16S mutation to ACH-806 and control inhibitors^a

Compound	Susceptibility ± SD (μM) of the indicated repliconsa				Fold change (μM) atb
	Luc/NS3-4AR(S16)		Luc/NS3-4AR(C16)		EC50	EC90
	EC50	EC90	EC50	EC90
ACH-806	0.27 ± 0.04	2.35 ± 0.24	0.02 ± 0.00	0.24 ± 0.01	13.5	9.8
NNI-1	0.44 ± 0.13	2.84 ± 0.06	0.63 ± 0.03	3.04 ± 0.05	0.7	0.9
PI-1	0.38 ± 0.10	1.88 ± 0.08	0.64 ± 0.05	2.52 ± 0.03	0.6	0.7
NI-1	0.19 ± 0.00	0.86 ± 0.01	0.24 ± 0.01	0.90 ± 0.01	0.8	1.0

^aData shown are averages ± standard deviations of results from two independent experiments.

^bData represent fold changes in EC₅₀ and EC₉₀ relative to that seen with the Luc/NS3-4A^R(C16) replicon.